Conference call to be held on September 29 hosted by Piper Sandler.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Positive Buy Rating for BridgeBio Pharma’s Encaleret Driven by Promising Phase 2 Results and Significant Market Potential
- BridgeBio price target raised to $82 from $72 at UBS
- Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential
- BridgeBio Pharma: Poised for Growth with Promising Pipeline and Upcoming Catalysts
- BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact